Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bionano Genomics, Inc.BNGO · Entity 7831 | Chief Scientific Officer | October 01, 2018 | October 03, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bionano Genomics, Inc.
Report date October 01, 2018 · Filed October 03, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.77 · Expires 2028-09-30 | Direct | 23,230 |
Reported balance
After 2018-10-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-10-01 · Grant · Acquired 23,230 · Balance 23,230 F1: 25% of the shares subject to the stock option vest and become exercisable on October 1, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the stock option vest and become exercisable on October 1, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2018 Filed Oct 3, 2018 20:27 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 23,230 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001209191-18-053806 · doc4.xml · derivative · entry 1 Cao Han PHD · CIK 0001745596 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,230 Underlying: Common Stock · 23,230 shares Expires 2028-09-30 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on October 1, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 22:48 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | ConversionSeries D-1 Convertible Preferred Stock · Derivative | 104,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-048554 · doc4.xml · derivative · entry 8 Cao Han PHD · CIK 0001745596 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,433 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-42.8 basis. The shares have no expiration date. F1 · shares: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-42.8 basis. The shares have no expiration date. F1 · derivative.exercise_date: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-42.8 basis. The shares have no expiration date. F1 · derivative.expiration_date: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-42.8 basis. The shares have no expiration date. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 22:48 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | ConversionSeries D Convertible Preferred Stock · Derivative | 4,362,062 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-048554 · doc4.xml · derivative · entry 7 Cao Han PHD · CIK 0001745596 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 101,918 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-42.8 basis. The shares have no expiration date. F1 · shares: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-42.8 basis. The shares have no expiration date. F1 · derivative.exercise_date: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-42.8 basis. The shares have no expiration date. F1 · derivative.expiration_date: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-42.8 basis. The shares have no expiration date. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 22:48 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | ConversionSeries C Convertible Preferred Stock · Derivative | 52,720 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-048554 · doc4.xml · derivative · entry 6 Cao Han PHD · CIK 0001745596 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,231 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-42.8 basis. The shares have no expiration date. F1 · shares: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-42.8 basis. The shares have no expiration date. F1 · derivative.exercise_date: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-42.8 basis. The shares have no expiration date. F1 · derivative.expiration_date: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-42.8 basis. The shares have no expiration date. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 22:48 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | ConversionSeries B Convertible Preferred Stock · Derivative | 254,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-048554 · doc4.xml · derivative · entry 5 Cao Han PHD · CIK 0001745596 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,941 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-42.8 basis. The shares have no expiration date. F1 · shares: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-42.8 basis. The shares have no expiration date. F1 · derivative.exercise_date: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-42.8 basis. The shares have no expiration date. F1 · derivative.expiration_date: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-42.8 basis. The shares have no expiration date. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 22:48 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | ConversionCommon Stock | 2,433 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-048554 · doc4.xml · nonDerivative · entry 4 Cao Han PHD · CIK 0001745596 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,936 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-42.8 basis. The shares have no expiration date. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 22:48 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | ConversionCommon Stock | 101,918 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-048554 · doc4.xml · nonDerivative · entry 3 Cao Han PHD · CIK 0001745596 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,503 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-42.8 basis. The shares have no expiration date. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 22:48 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | ConversionCommon Stock | 1,231 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-048554 · doc4.xml · nonDerivative · entry 2 Cao Han PHD · CIK 0001745596 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,585 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-42.8 basis. The shares have no expiration date. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 22:48 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | ConversionCommon Stock | 5,941 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-048554 · doc4.xml · nonDerivative · entry 1 Cao Han PHD · CIK 0001745596 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,354 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-42.8 basis. The shares have no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.